Quan Funds is a venture capital firm that primarily focuses its investments on the international technology sector, targeting emerging private and public companies. Their strategy involves fundamental investing in profitable, high-growth businesses with quality management and attractive valuations, while also being opportunistic and making long-term strategic investments.
50% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (50% of deals). Average disclosed round size is $94.8M (across 5 rounds with reported amounts).
Portfolio
6
Fund Size
$1.1B
Top Stage
Series B
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Pinnacle Medicines | Series B | $89M | Mar 2026 |
| WWindward Bio | Series A | $200M | Jan 2025 |
 Adcentrx Therapeutics | Series A | $51M | Dec 2023 |
 OriCell Therapeutics | Series B | $120M | Aug 2022 |
| AActLight SA | Series C | — | May 2019 |
 Lumotive | Series B | $14M | — |
Top Co-Investors
OrbiMed2 shared
Novo Holdings1 shared
SR One1 shared
Omega Funds1 shared
RTW Investments1 shared
Pivotal bioVenture Partners1 shared
Eight Roads Ventures1 shared
Investiere1 shared
Amazon Industrial Innovation Fund1 shared
ITHCA Group1 shared
Gates Frontier1 shared
MetaVC Partners1 shared
USAA1 shared
Swisscom Venture1 shared
Grazia1 shared
TSVC1 shared
LAV1 shared
Foresite Capital1 shared
HanKang Capital1 shared
Last updated: 21 April 2026